85X0 Stock Chart & Stats
€0.17
-€0.03(-9.58%)
At close: 4:00 PM EST
€0.17
-€0.03(-9.58%)
Day’s Range― - ―
52-Week Range€0.15 - €0.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.55M
Enterprise Value€117.21
Total Cash (Recent Filing)€3.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 21, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding47,601,730
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.23
Price to Sales (P/S)146.53
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€157.76K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt reduces refinancing and interest‑rate risk and preserves headroom to pursue partnerships or raise equity without immediate interest burden. Over a 2–6 month horizon this structural liquidity flexibility lowers solvency pressure while operations or partner programs develop.
Fermentation Platform Serving Diversified End MarketsBioextrax’s fermentation platform producing microbial biopolymers targets food, cosmetics and industrial markets—segments with growing interest in bio-based materials. This structural end-market diversification supports repeat project opportunities and scalable manufacturing potential across industries.
Multiple Revenue Channels: Product Sales, Contract Work, LicensingThe company’s mix of product sales, contract development/production and licensing/royalties creates complementary cash channels. Customer‑funded development and milestone/licensing income can provide durable non‑product cash inflows and reduce reliance on upfront capex for commercialization.
Bears Say
Consistent Negative Operating And Free Cash FlowOperating and free cash flow are negative every reported year and cash burn accelerated in 2025, indicating the business is not self‑funding. Over a 2–6 month horizon this structural cash deficit increases the probability of external financing, which may be dilutive or constrain growth and R&D.
Negative Gross Profit And Persistent Deep LossesGross profit was negative in most years including 2024–2025 and net results are persistently deep, showing the current cost base exceeds revenue. Structurally unprofitable operations mean margins must improve materially or costs be reduced to achieve sustainable business economics over the medium term.
Declining Equity And Negative Returns On EquityEquity erosion from 2022–2025 and materially negative returns on equity indicate capital is being consumed by losses. This structural weakening reduces the firm's buffer to absorb further losses, raises likelihood of dilutive capital raises, and limits strategic flexibility in the near to medium term.
85X0 FAQ
What was Bioextrax AB’s price range in the past 12 months?
Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.
What is Bioextrax AB’s market cap?
Bioextrax AB’s market cap is €10.55M.
When is Bioextrax AB’s upcoming earnings report date?
Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 15 days.
How were Bioextrax AB’s earnings last quarter?
Bioextrax AB released its earnings results on May 20, 2026. The company reported -€0.008 earnings per share for the quarter, beating the consensus estimate of -€0.009 by <€0.001.
Is Bioextrax AB overvalued?
According to Wall Street analysts Bioextrax AB’s price is currently Overvalued.
Does Bioextrax AB pay dividends?
Bioextrax AB does not currently pay dividends.
What is Bioextrax AB’s EPS estimate?
Bioextrax AB’s EPS estimate is >-0.01.
How many shares outstanding does Bioextrax AB have?
Bioextrax AB has 47,601,730 shares outstanding.
What happened to Bioextrax AB’s price movement after its last earnings report?
Bioextrax AB reported an EPS of -€0.008 in its last earnings report, beating expectations of -€0.009. Following the earnings report the stock price went up 10.502%.
Which hedge fund is a major shareholder of Bioextrax AB?
Currently, no hedge funds are holding shares in DE:85X0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioextrax AB
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
Technical Analysis
Scandinavian Enviro Systems AB
―
Axolot Solutions Holding AB
―
Nordic LEVEL Group AB Class B
―
CirChem AB
―
Clemondo Group AB
―